Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Ortho Regenerative Technologies earns repeat 'Outperform' rating, premium price target from Noble Capital

Published 2022-07-28, 10:10 a/m
© Reuters.  Ortho Regenerative Technologies earns repeat 'Outperform' rating, premium price target from Noble Capital
TGTB34
-
NE
-

Noble Capital has repeated an 'Outperform' rating and C$1.35 (US$1.05) price target again tagged Ortho Regenerative Technologies Inc (CSE:ORTH) following news the first patient in the ORTHO-R rotator cuff Phase I/II trial has received surgical treatment.

Ortho said recently that it had begun enrolling patients in its US phase I/II clinical trial of rotator cuff tear repair after the first patient surgery was completed in its US phase I/II clinical trial of rotator cuff tear repair.

“Phase I could be fully enrolled in the next couple of months,” Noble analysts said in a note to clients. "If patient enrollment expectations hold. We consider the company's ORTHO-R/RESTORE platform safety profile to be excellent.”

READ: Ortho Regenerative Technologies initiates patient enrollment following completion of first patient surgery in US phase I/II rotator cuff tear repair clinical trial

The ORTHO-R phase I/II clinical study is a prospective, randomized, controlled, and blinded clinical trial, to evaluate the safety and efficacy of its ORTHO-R soft tissue repair platform as an adjunct to standard of care surgery versus standard of care surgery alone for rotator cuff tear repair.

The Noble analysts said: “We believe Ortho RTI has a low-cost product platform that could substantially improve success rates in soft tissue surgeries.”

Additionally, the analysts pointed to a rebranding decision that came out of Ortho’s annual general meeting of shareholders on July 21, 2022. Shareholders approved a corporate name change, and the possible choices include Suregenix Inc, Chitogenx Inc and Vaskar Inc, among others.

Shares of Ortho Regenerative Technologies traded at C$0.26 on the CSE and US$0.20 on OTC Markets Thursday morning.

Ortho Regenerative Technologies is a clinical-stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries.

Read more on Proactive Investors CA

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.